Statement—NIH Study Finds Long-Acting Injectable Drug Prevents HIV Acquisition in Cisgender Women
"A pre-exposure prophylaxis (PrEP) regimen containing an investigational long-acting form of the HIV drug cabotegravir injected once every eight weeks was safe and more effective than a daily oral...
Read More